Last updated at 01 Jul 2024 11:48 AM
Director
DIN: 07757963
Samir Suresh Joshi is currently associated with 3 companies in various capacities such as Designated Partner, Director and Individual Promoter. They serve as a Director at MIRAJ NUCLEAR MEDICINE AND MOLECULAR IMA GING CENTER LLP and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 07757963.Samir Suresh Joshi is currently involved in 3 different roles. Their most recent position is with JYPLUS JOYEL PHARMA PRIVATE LIMITED as a Director. The first company Samir Suresh Joshi was appointed to as a director was MIRAJ NUCLEAR MEDICINE AND MOLECULAR IMA GING CENTER LLP. Samir Suresh Joshi is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Samir Suresh Joshi is currently associated with 3 companies in various capacities such as Designated Partner, Director and Individual Promoter. They serve as a Director at MIRAJ NUCLEAR MEDICINE AND MOLECULAR IMA GING CENTER LLP and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 07757963.Samir Suresh Joshi is currently involved in 3 different roles. Their most recent position is with JYPLUS JOYEL PHARMA PRIVATE LIMITED as a Director. The first company Samir Suresh Joshi was appointed to as a director was MIRAJ NUCLEAR MEDICINE AND MOLECULAR IMA GING CENTER LLP. Samir Suresh Joshi is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
4
Male
India
Gain instant access to verified contact details.
Current Companies (1)
Current LLPs (2)
Past Companies (0)
1y 9m 11 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| JYPLUS JOYEL PHARMA PRIVATE LIMITED | Director | 29-Sep-2022 |
| JYPLUS JOYEL PHARMA PRIVATE LIMITED | Individual Promoter | 29-Sep-2022 |